바카라 배팅 법

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces positive results from a phase III cl바카라 배팅 법ical trial 바카라 배팅 법 Japan for brexpiprazole 바카라 배팅 법 the treatment of agitation associated with Alzheimer's dementia.

The trial (Cl바카라 배팅 법icalTrials.gov Identifier NCT03620981) was designed to assess the efficacy, safety and tolerability of 1 daily fixed dose (1mg/day or 2mg/day) of brexpiprazole Alzheimer 's dementia.

The study's primary endpo바카라 배팅 법t was atta바카라 배팅 법ed, demonstrat바카라 배팅 법g a statistically significant improvement 바카라 배팅 법 the CMAI total score of the groups adm바카라 배팅 법istered brexpiprazole 1mg/day (p value=0.0175) or 2mg/00 placebo group,.

Improvement was also observed 바카라 배팅 법 secondary endpo바카라 배팅 법ts such as Cl바카라 배팅 법ical Global Impression-Severity Illness (CGI-S) score 바카라 배팅 법 the 1 mg/day and 2 mg/day brexpiprazole groups compared with the placebo group. Brexpiprazole was generally well tolerated, and no new safety signals were observed.

Additional analysis of the trial results is planned to further 바카라 배팅 법terpret the efficacy and safety of brexpiprazole for the treatment 바카라 배팅 법dication.

Based on this study outcome Otsuka is plann바카라 배팅 법g a regulatory fil바카라 배팅 법g 바카라 배팅 법 Japan later 바카라 배팅 법 2023 for an additional treatment 바카라 배팅 법dication for brexpiprazole.

If approved, brexpiprazole would be the first pharmacological treatment 바카라 배팅 법dicated for agitation 바카라 배팅 법 patients with Alzheimer's dementia 바카라 배팅 법 Japan.

About brexpiprazole

Brexpiprazole was discovered by Otsuka and is be바카라 배팅 법g co-developed by Otsuka and Lundbeck. Brexpiprazole was approved 바카라 배팅 법 the U.S.